Stock Analysis
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
Protagonist Therapeutics, Inc. (PTGX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Protagonist Therapeutics, Inc. (PTGX) currently has an AIQ Score of 73/100, indicating a bullish setup. Quality is the strongest factor at 81/100. Risk is the weakest current factor at 70/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PTGX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $130.95 |
| AIQ Score | 73/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $8.69B |
| P/E Ratio (TTM) | 25.39 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $3.32 |
| Revenue (Q3 FY2026) | $274.41M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.91 |
| Volume | 759.92K |
| 52-week range | $77.00-$160.81 |
| RSI 14 | 38.86 |
| 50-Day SMA | $140.30 |
| 200-Day SMA | $119.29 |
| Analyst Price Target | $176.80 |
| Next Earnings | Feb 24, 2027 |
PTGXProtagonist Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum70
- Value72
- Quality81
- Risk resilience70
- Sentiment—
PTGX Stock Analysis Summary
Protagonist Therapeutics, Inc. (PTGX) currently has an AIQ Score of 73/100, indicating a bullish setup. Quality is the strongest factor at 81/100. Risk resilience is the weakest current factor at 70/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, PTGX has AIQ Score of 73/100 with Quality base of 81/100 and fading Risk resilience at 70/100. Wait for component alignment before adding exposure.
Healthcare · -2.55% stock move · PTGX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PTGX Bullish or Bearish Right Now?
PTGX currently has a bullish overall setup. Quality is the strongest factor at 81/100, while Momentum is weakest at 70/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 81/100.
- - Momentum is constructive at 70/100.
- - Risk Resilience is supportive at 70/100.
- - Analyst target implies +35.01% upside from the latest quote.
- - Technical consensus has more sell votes than buy votes (35 vs 7).
Current Consensus
PTGX's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 4 neutral, and 35 sell votes. PTGX's 14-day RSI is 38.86, which places the stock in a weaker momentum range. PTGX's beta is 0.91, indicating market sensitivity broadly in line with the market.
What Changed in PTGX?
The largest recent change in PTGX is Momentum moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the PTGX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PTGX Decision Framework
Public evidence layers, setup checks, and risk context for Protagonist Therapeutics, Inc..
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
Protagonist Therapeutics, Inc. has an AIQ Score of 73/100 in a Bullish regime. Quality is strongest at 81/100. Beta is 0.91, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PTGX is in a Bullish AIQ regime with score 73/100. |
| Signal Conflict | The primary conflict is that quality leads at 81/100 while momentum lags at 70/100. |
| Factor Evidence | Momentum 70/100 · Value 72/100 · Quality 81/100 · Risk 70/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 81/100.
Momentum is 70/100 and RSI (14) is 38.9.
PTGX is in a Bullish regime at 73/100.
Risk factor is 70/100 with beta 0.91 and annual volatility 40.11%.
Current conflict: quality leads at 81/100 while momentum lags at 70/100.
PTGX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PTGX Fundamentals
PTGX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PTGX Technical Analysis
PTGX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PTGX Stock Catalysts
Track PTGX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PTGX Dividend Analysis
PTGX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PTGX Financial Data
PTGX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PTGX Risk Analysis
PTGX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PTGX Stock News
PTGX stock news, market tone, recent headlines, and catalyst context.
PTGX vs Biotechnology Peers
Current peer cohort: PTGX · PVLA · QURE · RAPP · RCUS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PTGX Current stock | 73/100 | 72/100 | 70/100 | 70/100 | 1.24 | 40.11% | Current |
| PVLA Palvella Therapeutics, Inc. | 70/100 | — | 84/100 | 47/100 | 1.12 | 84.47% | PTGX vs PVLA |
| QURE uniQure N.V. | 39/100 | 38/100 | 41/100 | 31/100 | 0.39 | 132.25% | PTGX vs QURE |
| RAPP Rapport Therapeutics, Inc. Common Stock | 43/100 | 42/100 | 33/100 | 39/100 | 0.35 | 62.34% | PTGX vs RAPP |
| RCUS Arcus Biosciences, Inc. | 39/100 | 43/100 | 34/100 | 42/100 | 0.05 | 62.65% | PTGX vs RCUS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for PTGX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PTGX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PTGX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PTGX Stock FAQ
What is PTGX stock price today?
Protagonist Therapeutics, Inc.'s current stock price is $130.95. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PTGX bullish or bearish right now?
PTGX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PTGX's market cap?
PTGX's market cap is $8.69B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PTGX's current P/E ratio?
PTGX's current P/E ratio is 25.39 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PTGX's RSI?
PTGX's 14-day RSI is 38.86 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PTGX above its 50-day and 200-day moving averages?
PTGX is -6.66% from its 50-day SMA and 9.77% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PTGX's next earnings date?
PTGX's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PTGX pay a dividend?
PTGX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.